News NICE backs NHS use of Autolus' leukaemia CAR-T Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.
Patients Overseas doctors are keeping the NHS alive: It’s time we sto... As a loud minority pushes Britain towards devolved nationalism, it’s worth remembering this sobering truth: without immigrants, there would be no NHS.
News Alnylam's ATTR cardiomyopathy drug backed for NHS use Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.
Market Access Why the NHS remains the world's most challenging – and rewar... For pharmaceutical, biotech, and medtech companies eyeing global expansion, the NHS presents a paradox.
News NICE backs five AI tools for bowel cancer screening Five AI technologies used during a colonoscopy exam to help detect the early signs of bowel cancer have been backed for use by the NHS in England.
News NICE backs Roche's non-Hodgkin lymphoma drug Columvi NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.